EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed
setting. There is no standard treatment, and the few small studies that have been conducted
have reported dismal outcomes. The purpose of this study is to pilot the use of EPOCH plus
rituximab in previously treated AIDS-related lymphoma. Clinical endpoints of the study
include toxicity and response. Progression-free and overall survival will be measured.
Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation,
c-myc and EBV when possible.
Allocation: Randomized, Primary Purpose: Treatment
Toxicity and activity of EPOCH during and at the completion of study treatment
Wyndham H Wilson, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|